Recent Updates
Recently added Catalysts
MDAI Positive Sentiment

Spectral AI Announces Repricing of its Public Warrants

Key Takeaway: Spectral AI has announced a repricing of its publicly-traded common share purchase warrants, reducing the exercise price from $11.50 to $2.75 per share. This change applies to all 8,433,333 outstanding warrants and follows a twenty-day notice period. The company could potentially raise up to $23 million if all warrants are exercised. Spectral AI specializes in using AI technology for advanced medical diagnostics, particularly in wound care management.
Price reaction · baseline $1.31 (2024-11-25 close) · hit after-hours · 1 other MDAI headline(s) in the window, move may be shared
day 0 close
+10.7%
day 1
+11.5%
day 3 · peak
+67.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Repricing of warrants significantly reduces exercise price, making investment more attractive.
  • Potential for the company to raise up to $23 million if all warrants are exercised.
  • Company's focus on AI in medical diagnostics presents strong growth potential in wound care.

Full Press Release Details

DALLAS, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable faster, more accurate treatment decisions in wound care, today announced the repricing of its 8,433,333 publicly-traded common share purchase warrants with an exercise price of $11.50 per share to $2.75 per share, effective following its twenty day notice requirement. The warrants currently trade on NASDAQ under the symbol MDAIW.
Pursuant to the terms of the Warrant Agreement, each warrant entitles the registered holder to purchase shares of common stock at the specified price, subject to adjustments outlined in the Warrant Agreement. The repricing was executed in accordance with the Company's discretion, as permitted under the Warrant Agreement, and applies uniformly to all outstanding warrants. The Company shall provide at least twenty (20) days prior written notice of such reduction to the registered holders of the Warrants.
If all of the warrants are exercised for cash, Spectral AI may receive up to an aggregate of approximately $23 million in net proceeds.
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize wound care management by "Seeing the Unknown®" with its DeepView® System. DeepView is a predictive device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, DeepView is expected to provide faster and more accurate treatment insight toward value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s intention to separate its Spectral IP subsidiary from the Company, and each Company’s strategy, plans, objectives, initiatives, strategic goals, financial outlook or other non-historical matters. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Spectral AI undertakes no obligation to update any forward-looking statements except as otherwise required by law.
For Media and Investor Relations, please contact:
Atlanta Capital Partners LLC

Frequently Asked Questions

What is the new exercise price for Spectral AI's warrants?

The new exercise price for Spectral AI's warrants is $2.75 per share.

How many warrants did Spectral AI reprice?

Spectral AI repriced 8,433,333 publicly-traded common share purchase warrants.

What is the purpose of Spectral AI's DeepView System?

The DeepView System aims to provide faster, accurate assessments of wound healing potential.

How much net proceeds could Spectral AI receive from warrant exercises?

If all warrants are exercised for cash, Spectral AI may receive about $23 million.

Where can more information about DeepView be found?

More information about DeepView is available at www.spectral-ai.com.

Last updated: Nov 26, 2024